From: A validation study of crescents in predicting ESRD in patients with IgA nephropathy
Variables | Overall | C0 | C1 | C2 |
---|---|---|---|---|
(n = 1152) | (n = 619) | (n = 447) | (n = 86) | |
Follow-up (months) | 45 (25–70) | 45 (24–70) | 43 (26–68) | 59 (27–88) |
eGFR decline rate (ml/min/1.73 m2/year) | − 1.1 (− 4.6 to − 1.8) | − 1.2 (− 4.6 to − 1.6) | − 1.0 (− 4.3 to − 2.0) | − 0.25 (− 4.6 to − 3.43) |
Male (%) | 566 (49.1) | 304 (49.1) | 221 (49.4) | 41 (47.7) |
Age (years) | 35.4 ± 12.0 | 36.5 ± 12.1 | 34.3 ± 11.9* | 33.0 ± 10.6* |
Urinary protein (g/d) | 1.42 (0.72–2.62) | 1.19 (0.62–2.39) | 1.44 (0.82–2.71)* | 2.51 (1.62–3.99)** |
eGFR (ml/min/1.73 m2) | 79.12 (52.08–101.67) | 78.46 (48.37–103.41) | 81.67 (56.59–100.82) | 65.95 (47.11–91.95)* |
Hypertension (%) | 381 (33.1) | 217 (35.1) | 134 (30.0) | 30 (34.9) |
MAP (mmHg) | 95.8 ± 13.5 | 96.2 ± 13.3 | 94.9 ± 13.3 | 97.6 ± 16.2 |
Oxford classification | ||||
 M1 (%) | 469/1089 (43.1) | 208/586 (35.5) | 217/425 (51.1)** | 44/78 (56.4)** |
 E1 (%) | 459/1089 (42.1) | 157/586 (26.8) | 239/425 (56.2)** | 63/78 (80.8)** |
 S1 (%) | 839/1089 (77.0) | 422/586 (72.0) | 363/425 (85.4)** | 54/78 (69.2) |
 T1 + T2 (%) | 364/1089 (33.4) | 195/586 (33.3) | 133/425 (31.3) | 36/78 (46.2)* |
With immunosuppression (%) | 566/1078 (52.5) | 288/578 (49.8) | 210/416 (50.5) | 68/84 (81.0)** |